Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer

被引:140
作者
Sasaki, H
Yu, CY
Dai, MR
Tam, C
Loda, M
Auclair, D
Chen, LB
Elias, A
机构
[1] Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Cambridge, MA 02138 USA
[3] Harvard Univ, Sch Med, Dept Canc Biol, Cambridge, MA 02138 USA
关键词
bone metastasis; cell adhesion; tumor invasion;
D O I
10.1023/A:1021899904332
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Periostin is a recently identified gene that is preferentially expressed in periosteum, indicating a potential role in bone formation and maintenance of structure. We independently identified and isolated periostin from cancer tissue, using the palindromic PCR-driven cDNA Differential Display technique. For the present work, we developed a novel sandwich chemiluminescence assay to detect serum periostin level using newly developed monoclonal and polyclonal antibodies. We investigated serum periostin levels in breast cancer and small cell lung cancer patients, especially in patients with bone metastasis. The study included 58 breast cancer and 44 small cell lung cancer patients. Serum periostin levels were elevated in breast cancer patients presenting with bone metastases (92.0 +/- 28.6 ng/ml) compared to similar breast cancer patients without evidence of bone metastasis (55.0 +/- 16.6 ng/ml, p = 0.04). No correlation was found between the serum periostin level and any other prognostic factors, such as clinical stage and lymph node metastasis in breast cancer. Serum periostin levels thus appear to serve as a marker of bone metastasis from breast cancer. In contrast, serum periostin levels were similar in samples from patients with small cell lung cancer who did or did not have bone metastasis. However, increasing T-stage and N-stage of patients with small cell lung cancer were correlated with higher periostin levels (T4, 126.5 +/- 29.7 ng/ml v.s. T2, 64.9 +/- 16.1 ng/ml, p = 0.03; and T4 v.s. T1, 36.3 +/- 7.5 ng/ml, p = 0.01; N3, 108.7 +/- 17.3 ng/ml v.s. N2, 49.7 +/- 10.9 ng/ml, p = 0.01). Periostin has a substantial homology with the insect cell adhesion molecule, fasciclin I. Thus, expression of periostin may facilitate tumor cell adhesion to the bone surface. In fact, we found by in situ RNA hybridization, that the periostin gene was highly expressed in the stromal cells immediately surrounding the tumor, but not within the breast cancer cells themselves.
引用
收藏
页码:245 / 252
页数:8
相关论文
共 32 条
[1]  
ABRAMS HL, 1950, CANCER, V3, P74, DOI 10.1002/1097-0142(1950)3:1<74::AID-CNCR2820030111>3.0.CO
[2]  
2-7
[3]   Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer [J].
Aruga, A ;
Koizumi, M ;
Hotta, R ;
Takahashi, S ;
Ogata, E .
BRITISH JOURNAL OF CANCER, 1997, 76 (06) :760-764
[4]  
Bao SD, 1999, CANCER RES, V59, P2023
[5]  
Bellahcene A, 1997, B CANCER, V84, P17
[6]   Expression of bone sialoprotein in human lung cancer [J].
Bellahcene, A ;
Maloujahmoum, N ;
Fisher, LW ;
Pastorino, H ;
Tagliabue, E ;
Menard, S ;
Castronovo, V .
CALCIFIED TISSUE INTERNATIONAL, 1997, 61 (03) :183-188
[7]   Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma [J].
Blomqvist, C ;
Risteli, L ;
Risteli, J ;
Virkkunen, P ;
Sarna, S ;
Elomaa, I .
BRITISH JOURNAL OF CANCER, 1996, 73 (09) :1074-1079
[8]   PARATHYROID-HORMONE RELATED PROTEIN AND SKELETAL MORBIDITY IN BREAST-CANCER [J].
BUNDRED, NJ ;
WALKER, RA ;
RATCLIFFE, WA ;
WARWICK, J ;
MORRISON, JM ;
RATCLIFFE, JG .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :690-692
[9]   PRELIMINARY-RESULTS OF THE USE OF URINARY-EXCRETION OF PYRIDINIUM CROSS-LINKS FOR MONITORING METASTATIC BONE-DISEASE [J].
COLEMAN, RE ;
HOUSTON, S ;
JAMES, I ;
RODGER, A ;
RUBENS, RD ;
LEONARD, RCF ;
FORD, J .
BRITISH JOURNAL OF CANCER, 1992, 65 (05) :766-768
[10]  
Diel IJ, 1999, CLIN CANCER RES, V5, P3914